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Purpose. To investigate in vivo the acute host response to an alternative implant designed for the treatment of stress urinary
incontinence (SUI) and pelvic organ prolapse (POP). Methods. A biodegradable scaffold was produced from poly-L-lactic acid
(PLA) using the electrospinning technique. Human and rat adipose-derived stem cells (ADSCs) were isolated and characterized by
fluorescence-activated cell sorting and differentiation assays. PLA scaffolds were seeded and cultured for 2 weeks with human or rat
ADSCs. Scaffolds with and without human or rat ADSCs were implanted subcutaneously on the abdominal wall of rats. After 3 and
7 days, 6 animals from each group were sacrificed. Sections from each sample were analyzed by Haematoxylin and Eosin staining,
Sirius red staining, and immunohistochemistry for CD68, PECAM-1, and collagen I and III. Results. Animals responded to the
scaffolds with an acute macrophage response. After 7 days of implantation, there was extensive host cell penetration, new blood
vessel formation, and new collagen deposition throughout the full thickness of the samples without obvious differences between
cell-containing and cell-free scaffolds. Conclusions. The acute in vivo response to an alternative implant (both with and without
cells) for the treatment of SUI and POP showed good acute integration into the host tissues.
1. Introduction
Surgical implantation of both natural and synthetic cell-free
materials is the current standard of care in many parts of
the world in the treatment of stress urinary incontinence
(SUI) and pelvic organ prolapse (POP) [1]. Autologous fascia,
long used as a sling material for SUI, requires specialized
training and is limited by the amount that can be harvested
with associated donor site morbidity [2]. Nondegradable
polypropylene synthetic meshes, introduced as a less invasive
alternative, have been widely used over the past decade;
nevertheless, increasing reports of serious complicationswith
these materials such as vaginal or urinary tract exposure,
chronic pain, and voiding dysfunction are now emerging
[2–4].
Although many factors may influence the outcome of
mesh surgery, including physical properties of the material
and surgical and constitutional factors [1], the host response
is particularly important. Nondegradable polypropylene
implants cannot be remodelled and induce release of
cytokines, and some patients respond to them with chronic
inflammation followed by an unsuitable fibrosis which can
lead to the above complications [5]. Alternatively, the out-
comes of using degradable biological grafts, trialled in limited
clinical studies, are mixed. Animal collagen grafts have been
found to fail due to quick degradation and while chemical
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cross-linking overcomes this it can result in poor graft
integration [6].
We have previously shown the potential of poly-lactic
acid (PLA), an FDA approved polymer synthesized into a
microfiber scaffold, to develop in vitro into an engineered
tissue when seeded with adipose derived stem cells (ADSCs)
producing the key extracellularmatrix (ECM) proteins [7]. In
addition, we also showed in vitro that PLA scaffolds are more
biocompatible than polypropylene meshes with mechanical
properties close to those of native tissues [8].
Therefore, we aim to develop an alternative material
for the treatment of SUI and POP which degrades slowly
while the introduction of autologous cells to these scaffolds
will produce new ECM. We hypothesise that the absorbable
material is less likely to result in exposure through vaginal
tissues and the cellular component will encourage tissue
regeneration and good integration in the host tissues leading
to better outcomes than current materials used to treat SUI
and POP.
Since the acute host response elicited by any biomaterial is
critical to its integration into the host tissues [9], in this study,
we sought to assess this response in animals by comparing
PLA scaffolds implanted with and without human ADSCs.
Rat ADSCs were also included in this study as an allogeneic
implantation control.
2. Materials and Methods
Scaffold production and human ADSCs isolation were
performed in the Kroto Research Institute, University of
Sheffield. Cells and PLA scaffolds were sent to the Laboratory
of Experimental Gynaecology, University Hospital Leuven,
for sample preparation. Rat ADCSs isolation and characteri-
zation of rat and human ADSCs were also carried out in this
laboratory. Animal surgery was conducted in the Centre for
Surgical Technologies, Katholieke Universiteit Leuven. After
the sacrifice, samples were paraffin fixed in the Laboratory
of Experimental Gynecology and histological analysis was
conducted at the Kroto Research Institute.
2.1. PLA Scaffold Synthesis. A 10% PLA solution (Sigma-
Aldrich,Dorset, UK) dissolved in dichloromethanewasmade
(w/v). PLA scaffolds were produced aseptically by electro-
spinning as previously described [7]. Thereafter scaffolds
were heat-annealed in a dry oven at 60∘C for 3 hours.
2.2. ADSCs Isolation and Culture. ADSCs were sourced from
human subcutaneous fat donated on an anonymous basis
under a research tissue bank licence (number 08/H1308/39)
under the Human Tissue Authority. Isolation and culture
were performed as previously described from 10mL of fat
tissue [7]. Cells at passage 4 were cryopreserved in 1mL of
10% DMSO (dimethyl sulfoxide) in fetal calf serum (FCS)
(Advanced Protein Products, BrierleyHill, UK).Once in Leu-
ven, cells were resurrected and then maintained at 37∘C and
5% CO
2
with Dulbecco’s Modified Eagle’s Medium (DMEM)
supplemented with 10% FCS, 1% penicillin/streptomycin, 1%
glutamine, and 0.25% fungizone (Gibco Invitrogen, Paisley,
UK) (all experiments were in DMEMmedium plus 10% FBS
unless stated otherwise). Cells were used at passage 6 in
experiments.
All animal procedures were approved by the ethical
committee of the Katholieke Universiteit Leuven with the
project number P163 2011.
After isoflurane anaesthesia, Sprague-Dawley rats were
sacrificed by cervical dislocation. After laparotomy, subcuta-
neous fat was processed to isolate rat ADSCs following the
above human ADSCs isolation protocol. Cells at passage 4
were used in experiments.
2.3. Fluorescence-Activated Cell Sorting (FACS). Human
ADSCswere characterized using flowcytometry analysis [10].
100,000 cells were harvested and incubated with either FITC
or PE-conjugated antibodies against human CD24, CD90,
CD44, CD105, CD73, HLA-ABC,HLA-DR, CD34, andCD45
(BD Bioscience, Erembodegem, Belgium) and CD29 (Acris,
Herford, Germany) mouse anti-human monoclonal anti-
bodies and appropriate isotype controls. Stained cells were
analyzed using a BecktonDickinson flow cytometer (Beckton
Dickinson, Franklin Lakes, NJ, USA) using the Cell Quest
software and data were analysed using the FlowJo software
(Tree Star, Ashland, OR, USA).
The same analysis was performed for rat ADSCs using
either FITC or PE-conjugated antibodies against rat I-E[𝜅]
CD90, CD44, CD31, CD45, and CD11b (BD Bioscience) and
CD29 (Acris) mouse anti-rat monoclonal antibodies and
appropriate isotype controls.
2.4. Differentiation Assays. The multipotency potential of
human and rat ADSCswas evaluated by differentiation assays
as previously described [11].
After 3 weeks in culture with osteogenic or adipogenic
medium, cells were fixed and stained by incubation for
30 minutes with 1mg/mL Alizarin Red solution (Sigma-
Aldrich) or filtered 0.3% Oil Red O (Sigma-Aldrich) in 60%
isopropanol (Fisher Scientific, UK Ltd.) (w/v), respectively.
2.5. Scaffold Preparation and Cell Seeding. Sterile PLA scaf-
folds of 1.5 × 1.5 cm were seeded with 500,000 human or rat
ADSCs using steel rings as a seeding well of 1 cm diameter.
All samples were cultured in DMEM medium at 37∘C in a
5% CO
2
atmosphere. We also included cell-free scaffolds in
medium as controls.
2.6. Implantation. After 2 weeks in culture, 3 groups of sam-
ples were implanted—plain PLA scaffolds and PLA scaffolds
cultured with human or rat ADSCs. Only one sample was
implanted in every female Sprague-Dawley female rat with
12 rats per each of the 3 groups (36 rats in total).
Animals were placed in 100% isoflurane (Isoba) and kept
under isoflurane anaesthesia via a nose cone. After the belly
of the animal was shaved and disinfected, the abdominal
skin was incised and flaps of the subcutaneous layer were
raised (Figure 1). Samples were sutured on the abdominal
wall with nonabsorbable sutures (Prolene∗ (4-0/RB-1 17mm
1/2c; Ethicon, Groot Bijgaarden, Belgium)) on each corner.
BioMed Research International 3
(a1) (a2) (a3)
(b)
PLA scaffold cultured with ADSCs
integrated into the fascia of the abdominal wall
(c)
Abdominal 
wall
Sample
2.5mm
Figure 1: Animal surgical procedure. (a1) Skin incision and flaps of subcutaneous layer were raised from the top of the abdominal wall.
(a2) Suture of sample at four corners. (a3) Subcutaneous and skin layers closure. (b) Animals sacrificed and appearance of sample on top
of abdominal wall. (c) Representative light microscopy H&E stained panoramic image of the abdominal wall of female Sprague-Dawley rat,
after 3 days of implantation of PLA scaffold on top, previously cultured with human ADSCs in DMEMmedium for 2 weeks.
Subcutaneous layer and skin were closed with resorbable
sutures (Vicryl∗ (2-0/FS-1 24mm 3/8c, Ethicon)). Animals
were weaned from anaesthesia and observed for recovery.
2.7. Sacrifice and Sample Fixation. At 3 and 7 days after
implantation, 6 animals from each group were sacrificed by
intracardiac injection of T-61 (embutramide 200mg, meben-
zonium iodide 50mg, and tetracaine hydrochloride 5mg, per
mL) (Intervet, International B.V.). Abdominal wall pieces of
2 cm2 containing implants on top were explanted (Figure 1).
Samples were fixed in 10% neutral buffered formalin and
paraffin embedded (Chandon CITADEL 1000, HVL).
2.8. Histology. Sections 6 𝜇m thick were cut from the paraffin
embedded samples with a microtome (Leica TP 1020 Auto-
matic Tissue Processor) and placed on Superfrost plus slides
(Menzel-Gla¨ser, Denmark).
Conventional Haematoxylin and Eosin (H&E) staining
was performed as previously described [12]. Slides were then
mounted in DPX mounting medium (Fisher Scientific) with
a coverslip.
For immunohistochemistry procedure sections were
rehydrated, then delineatedwith aDako pen, and treatedwith
0.05% trypsin (Sigma-Aldrich) for 20 minutes at 37∘C. The
samples were blocked using donkey serum (ImmunoCruz
goat ABC Staining System, Santa Cruz Biotechnology, Inc.)
for 1 hour. Sections were incubated with one of four mon-
oclonal antibodies overnight: mouse anti-rat CD68 (1 : 200;
Abcam, UK), goat anti-rat PECAM-1 (1 : 50; Santa Cruz
Biotechnology, Inc.), goat anti-human collagen I (AbD
Serotec, Oxford, UK), and goat anti-human collagen III
(AbD Serotec, Oxford, UK). This was followed by 1 hour
incubation with secondary antibodies: biotinylated goat anti-
mouse Ig (1 : 200; BD, Pharmingen) and biotinylated anti-goat
Ig (1 : 200; ImmunoCruz goat ABC Staining System, Santa
Cruz Biotechnology, Inc.). After incubation with an avidin
and biotinylated horseradish peroxidase, the target proteins
were visualized by incubation in peroxidase substrate and
DAB chromogen (ImmunoCruz goat ABC Staining System).
Samples were then counterstained with Haematoxylin, dehy-
drated, and mounted as per H&E protocol.
Three groups of controls were performed—samples
incubated without primary and secondary antibodies, or
incubated only with secondary antibodies. Semiquantitative
assessment of the extent of immunostaining was done on
a blinded observer basis using a qualitative grading scale;
absent = 0,mild presence = 1, large presence = 2, abundance =
3, and great abundance = 4. Example photographs depicting
0, 1, 2, 3, and 4 were provided for reference and the median
value from these scores was used [7].
For total collagen staining, sections were rehydrated,
following the same protocol as for H&E, and then incubated
with Sirius red (0.1% w/v Direct Red 80 in saturated picric
acid, Sigma-Aldrich) for 1 hour. Samples were then rinsed
briefly in distilled water and washed in acidified water (0.5%
acetic acid, VWR International Ltd.) for 1 minute. Finally
samples were dehydrated and mounted as per the H&E
protocol.
2.9. Statistics. Differences for the semiquantitative assess-
ment of the extent of immunostainingwere statistically tested
against a null hypothesis of no difference between samples
using a two-sample Student’s 𝑡-test with equal variance not
assumed (significance = 𝑃 < 0.05).
3. Results
Human and rat ADSCs were positively and negatively char-
acterized by expression of specific cell surface antigens,
as previously described [10], and by their differentiation
potential (Figure 2).
All animals survived both the operation and the period
of implantation without any observed alteration in their
physiological functions. No signs of infection were observed
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Figure 2: Continued.
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Figure 2: Characterization of ADSCs. Rat (a) and human (b) ADSCs isolated from subcutaneous adipose tissue characterized by FACS
showing fluorescent intensity for bare cells in red colour, for isotypes controls in orange colour, and for each specific antigen marker in blue
colour. At the bottom, differentiation assays showing potential for osteogenic (c2) and adipogenic (c3) lineages, preceded by human ADSCs
cultured in DMEMmedium as control (c1).
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Figure 3: Morphological appearance of the implanted samples. Representative light microscopy H&E stained sections of abdominal wall of
female Sprague-Dawley rat after 3 and 7 days of implantation of PLA scaffold on top, previously cultured with and without (control) rat or
human ADSCs in DMEM medium for 2 weeks. At 7 days, all samples presenting several small blood vessels are identified by (↑). Scale bars
of 0.2mm for images from 3 days implantation and 0.1mm for images from 7 days implantation. (S) Sample; (F) Fascia; and (SM) Skeletal
Muscle.
when harvesting the samples and all of them (PLA scaffolds
previously cultured with and without cells) were identified
on the subcutaneous fascia which covers the abdominal wall
muscles (Figure 1).
After 3 days of implantation, host cells infiltrated samples,
as seen in samples implanted without cells for H&E staining.
After 7 days the cell infiltration was increased in all samples,
and new small blood vessels were visible inside the samples
(Figure 3).
At day 3, CD68 positive cells were seen throughout the
samples, localized inside them and not found in the sur-
rounding tissues (Figure 4). Semiquantitative assessment of
the immunohistochemistry demonstrated this staining to be
moderate, becoming more intense after 7 days implantation
(Figure 5).
Amoderate PECAM-1 staining was identified after 3 days
with no differences between groups. By 7 days, there was
a similar expression between samples with rat or human
6 BioMed Research International
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Figure 4: Assessment of the acute host response against the implanted samples. Representative light microscopy image of sections of
abdominal wall of female Sprague-Dawley rats after 3 and 7 days of implantation of PLA scaffold on top, previously cultured with and without
(control) rat or humanADSCs inDMEMmedium for 2weeks; following immunohistochemistry for anti-CD68 antibody (a) or anti-PECAM-
1 antibody (b). (a) Macrophages surrounding individual PLA fibres are identified by (↑). (b) Endothelial cells stained for PECAM-1 around
blood vessels are identified by (↑). Scale bars of 0.1mm. (S) Sample; (F) Fascia.
ADSCs but statistically lower staining for cell-free samples
(Figure 5). Although PECAM-1 stained many cells inside the
samples, similarly to CD68, this was also identified around
large blood vessels in the abdominal fascia at day 3; while,
after 7 days of implantation, new small blood vessels inside
all samples were stained (Figure 4).
After 3 days of implantation, immunohistochemistry for
collagen III and Sirius red staining for total collagen revealed
a thin layer of collagen production on the lower surface of all
the samples, and at day 7, thin new collagen fibres were visible
throughout the samples (Figure 6). Collagen I staining at day
3 was minimally found around cells inside samples and only
for samples implanted with human or rat cells; although, after
7 days, this minimal staining was found inside all samples
(Figure 6).
4. Discussion
Since the U.S. Food and Drug Administration announced
serious complications with current surgical meshes used to
treat POP and SUI [13], several studies have investigated the
host response in animals to different cell-free synthetic and
biological materials. This is viewed as a critical indicator in
predicting their long-term outcomes [14–16].
Many animal studies show that polypropylene meshes
provoke a fairly pronounced inflammation leading to a
massive cell infiltration into the scaffold andultimately to new
collagen production described as a vigorous fibrotic process
[17–19].These studies also reported an increase in the stiffness
of polypropylene after its implantation due to this fibrosis.
Some fibrosis may be desirable for successful outcomes when
treating SUI or POP. This is an area where it is currently
difficult to obtain data correlating patient’s responses to clini-
cal outcome. Alternatively, irreversible plastic deformation of
this material may explain why it could “cheesewire” through
the patient’s tissues leading to exposure in some patients.
To improve integration into native tissues, a few groups
have investigated in vitro and in hernia repair animal mod-
els light polypropylene meshes which have been modified
by surface coating with collagen, titanium, or absorbable
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Figure 5: Semiquantitative analyses of the host response against the
implanted samples. Assessment of the extent of immunohistochem-
istry using a blind scoring for the expression of CD68 and PECAM-
1 from sections of abdominal wall of female Sprague-Dawley rat
after 3 and 7 days of implantation of PLA scaffold on top, previously
cultured with and without (control) rat or humanADSCs in DMEM
medium for 2 weeks. Results shown as mean ± SEM (𝑛 = 6). Scale: 0
= absent, 1 = mild presence, 2 = large presence, 3 = abundance, and
4 = great abundance.
polymers. While some of these animal studies found higher
biocompatibility for the polypropylene light meshes com-
pared to the polypropylene control group [20, 21], others
found that the outcomes were very similar between the two
groups [22]. Some of thesemeshes have now been introduced
into the market since these are thought to be associated
with lower complications. However, a review of randomized
controlled trials using these meshes for human hernia repair
found higher recurrence rates compared to conventional
polypropylene meshes [23].
On the other hand, the tissue engineering field has
recently introduced new biomaterials which can be used for
several clinical applications. Neural stem cells or osteoblasts
have been combined with electrospun PLA scaffolds with
potential for peripheral nerve repair [24] and as a bone
substitute [25], respectively.
In addition, PLA monofilament meshes have been
assessed in vivo with an incisional hernia Wistar rat model
used to simulate vaginal wall repair [26]. Compared to
polypropylene, the PLA scaffold retained an acceptable
strength 8 months after implantation, showed a significantly
lower inflammatory response, and the collagen produced was
better organized.The same authors also reported PLAmeshes
to have less infection risk compared to other meshes in a rat
infected abdominal model [27].
Similarly to our study, only two research groups have
previously assessed in animals an engineered tissue for the
treatment of SUI and POP which were developed from
biodegradable polyglycolic acid (PGA) [28] or poly-lactic-
glycolic acid (PLGA) [13] scaffolds. Both studies found
good integration into host tissues with neofascia formation.
However, the rate of degradation of scaffolds in vivo is rapid
(within weeks) for PGA and proportionally slower as PLA,
which is much slower to degrade, is added to the polymer
solution. Our group has shown in vivo that electrospun
scaffolds of 50% PGA and 50% PLA are degraded within 8
weeks in rats and PLGA (75/25) scaffolds last for more than
3 months whilst PLA scaffolds are present after 12 months of
implantation [12]. Thus the rate of breakdown is tunable and
predictable and has relevance to maintenance of mechanical
properties of the implants.
The current study also aimed to explore the acute
response to the use of mesenchymal stem cells which have
been already used in women [29] to treat SUI by cell injection
into the urethral sphincter and submucosa.
Large numbers of these cells can be quickly isolated
using a minimally invasive liposuction in humans [30].
ADSCs do not differentiate when cultured in basic DMEM
medium, displaying fibroblastic behavior and producing an
endogenous ECM [31]; in addition to this, they have been
shown to release a growth factor to stimulate fibroblast
proliferation with the potential to regenerate connective
tissues [32]. Furthermore, ADSCs have the potential to
inhibit inflammatory responses by secretion of the inhibitor
of tumor necrosis factor𝛼 [32] and a subpopulation ofADSCs
expresses an endothelial surface antigen (CD34) which can
promote neovascularization [33].
In our study we implanted human cells in immunocom-
petent Sprague-Dawley rats; however, rat cells were included
as a control. All samples were implanted in different rats
since interpretation of responses to different materials in the
same animal is not recommended with a body wide immune
response.
ADSCs were well characterized prior to implantation but
they were not tracked post implantation so it is not possible
to comment on any direct regenerative effect of these cells.
Alternatively, after few days implantation the major aspect
to assess was the host inflammatory response elicited against
these implants and, actually, this was very similar for cell-free
scaffolds and those seeded with human or rat ADSCs.
All PLA scaffolds, both without and with cells, were
integrated into the fascia of the abdominal wall with rapid
host cell infiltration and ingrowth of small blood vessels.
Themacrophage response against all sampleswas evident,
particularly 7 days after implantation as identified by CD68+
cells [9]. This response seems to be specific to the synthetic
foreign material since macrophages were not found in tissues
surrounding the samples and macrophages enclosed individ-
ual PLA fibres (Figure 4).
Although PECAM-1 is expressed on platelets and sub-
sets of leukocytes, it mainly stains endothelial cells with
cell adhesion, transendothelial migration of myeloid-derived
cells, and angiogenesis functions; and therefore, it has been
widely used to assess neovascularization [9]. Since PECAM-
1 staining was higher at day 7 for cell-seeded samples
compared to samples implanted without cells, this could be
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Figure 6: Assessment of new extracellular matrix formation in the samples implanted. Representative light microscopy of sections of
abdominal wall of female Sprague-Dawley rat after 3 days of implantation of PLA scaffold on top, previously cultured with and without
(control) rat or human ADSCs in DMEM medium for 2 weeks; following immunohistochemistry for anti-collagen I and anti-collagen III
antibodies, or Sirius red staining. Scale bars of 0.2mm for images from 3 days implantation and 0.1mm for images from 7 days implantation.
(S) Sample; (F) Fascia; and (SM) Skeletal Muscle.
interpreted as more myeloid-derived cell infiltrates and/or
higher neovascularization as identified by small blood vessels
inside cell-seeded samples.
Macroporous polypropylene mesh is said to be more
favourable to permit host cell infiltration [2]. The current
study shows that a microporous electrospun PLA scaffold
permitted the infiltration of macrophages throughout its
entire thickness which means that this scaffold is no barrier
to macrophage activity so their ability to tackle bacterial
infection would not be compromised. Additionally, the host
cell infiltration led to ECM formation, as seen particularly for
collagen III, which is indicative of remodelling of the implant
leading to good integration into host tissues [9]. Alternatively,
collagen I was minimally detected in all samples and, at day
BioMed Research International 9
3, it was only found in samples implanted with human or rat
cells whichmay suggest production of this by the cells during
the initial period of their culture in vitro [7].
In animal studies, the host response to materials used to
treat SUI and POP is often analyzed after 7, 30, and 90 days
after implantation. While acute inflammatory responses and
integration into native tissues, including neovascularization
and ECM production, can be assessed in the short-term by
subcutaneous implantation in rats [34]; long-term implanta-
tion (30 and 90 days) usually in larger animals also allows the
evaluation of chronic immune responses and the evaluation
of any changes in mechanical properties after implantation
[17–19].
Therefore, the major limitations of this work are its
short-term nature since this model cannot be used to assess
whether a chronic immune response ensues or the regen-
erative/angiogenesis potential of the cell-seeded scaffolds.
Additionally, implanted ADSCs were not labelled, something
that will be necessary in longer-term experiments to provide
information on their survival or migration.
5. Conclusion
For all groups, an alternative implant designed for urog-
ynecology showed host cell infiltration, mainly due to a
macrophage response against the foreignmaterial as a normal
wound healing mechanism, which led to neotissue produc-
tion with new blood vessels formation—all early indicators of
constructive remodelling for long-term integration into host
tissues [9].
Our future experiments will now progress to a longer
term (3months) rabbit fascial-defect model to investigate the
development of any chronic immune response, the fate of the
ADSCs, and, very crucial, the biomechanical properties of the
implant after several months of implantation. Ultimately, our
ideal approach to achieve an economical final clinical product
would be to combine these scaffolds with patient’s cells just
before being surgically implanted on the same operation as
rapid extraction of ADSCs from fresh lipoaspirate is being
developed currently [35].
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